NeoCore Technology (4131) reported revenue of NT$19.9 million for Oct 2026, +34.9% year on year and +20.3% from the previous month. Revenue for Jan–Oct 2026 was NT$225.3 million (+16.6% year on year).
Year-on-year revenue growth: 3 months in a row. →
In Oct 2026, it ranked No. 124 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$19.9 million | +34.9% | +20.3% |
| Sep 2026 | NT$16.5 million | +1.5% | +3.6% |
| Aug 2026 | NT$16 million | +10.7% | -4.9% |
| Jul 2026 | NT$16.8 million | -31.5% | -50.8% |
| Jun 2026 | NT$34.1 million | +96.4% | +1.4% |
| May 2026 | NT$33.6 million | +135.4% | +20.2% |
| Apr 2026 | NT$28 million | +26.9% | +2.3% |
| Mar 2026 | NT$27.3 million | +41.7% | +71.4% |
| Feb 2026 | NT$16 million | -42.9% | -7.1% |
| Jan 2026 | NT$17.2 million | -23.2% | -30.1% |
| Dec 2025 | NT$24.6 million | +2,590.6% | -8.5% |
| Nov 2025 | NT$26.9 million | +396.7% | +82.0% |
| Oct 2025 | NT$14.8 million | +178.7% | -9.4% |
| Sep 2025 | NT$16.3 million | +238.3% | +13.0% |
| Aug 2025 | NT$14.4 million | +175.0% | -41.2% |
| Jul 2025 | NT$24.5 million | +281.4% | +41.1% |
| Jun 2025 | NT$17.4 million | +220.6% | +21.6% |
| May 2025 | NT$14.3 million | +166.7% | -35.2% |
| Apr 2025 | NT$22.1 million | +218.9% | +14.2% |
| Mar 2025 | NT$19.3 million | +226.0% | -30.9% |
| Feb 2025 | NT$27.9 million | +383.9% | +25.0% |
| Jan 2025 | NT$22.3 million | +448.7% | +2,347.8% |
| Dec 2024 | NT$913,000 | -64.0% | -83.1% |
| Nov 2024 | NT$5.4 million | -52.7% | +2.2% |
| Oct 2024 | NT$5.3 million | +21.1% | +10.0% |
Jan–Oct 2026 cumulative: NT$225.3 million (+16.6% YoY)
Other Biotech & Medical companies
Compare with peers: NeoCore Technology vs PEC / NeoCore Technology vs Lotus Pharm / NeoCore Technology vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16